Associated Papers
Frequency enrichment of coding variants in a French-Canadian founder population and its implication for inflammatory bowel diseases.
Bhérer C et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Potentially functional variants of PARK7 and DDR2 in ferroptosis-related genes predict survival of non-small cell lung cancer patients.
Wang H et al.
International Journal of Cancer, 2025
Investigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder.
Jia X et al.
Molecular Psychiatry, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.
Li J et al.
Journal of Translational Medicine, 2020
Family History of Colorectal or Esophageal Cancer in Barrett's Esophagus and Potentially Explanatory Genetic Variants.
Rubenstein JH et al.
Clinical and Translational Gastroenterology, 2020
Disruption of the PTHLH regulatory landscape results in features consistent with hyperparathyroid disease.
Deshwar AR et al.
American Journal of Medical Genetics. Part A, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Testa U et al.
Cancers, 2018
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lee MS et al.
Cancer Research and Treatment, 2017
Functional analysis of Discoidin domain receptor 2 mutation and expression in squamous cell lung cancer.
Kobayashi-Watanabe N et al.
Lung Cancer (amsterdam, Netherlands), 2017
Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
Xu C et al.
Molecular Cancer Therapeutics, 2015
Racial diversity of actionable mutations in non-small cell lung cancer.
Bollig-Fischer A et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2015
Tongue carcinoma infrequently harbor common actionable genetic alterations.
Tan DS et al.
Bmc Cancer, 2014
Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.
Okamoto I et al.
Oncotarget, 2014
Collagen recognition and transmembrane signalling by discoidin domain receptors.
Carafoli F et al.
Biochimica Et Biophysica Acta, 2013
Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants.
Iwai LK et al.
The Biochemical Journal, 2013
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS et al.
Cancer Discovery, 2011